It is found that astragaloside IV is able to inhibit liver inflammation via mitogen-activated protein kinase (MAPK)/nuclear factor kappa-B (NF-κB) signaling pathway, which in turn reduce lipid levels, hepatic steatosis in hyperlipidemic mice (Zhang Y. et al., 2022). This evidence concerns the gene NFKB1 and Hepatic steatosis.